[6-K] Evotec SE Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Evotec SE reported it has signed a final agreement with Sandoz. According to the company’s announcement, the transaction could result in payments potentially over US$ 650 m, plus royalties tied to a portfolio of up to 10 biosimilar molecules.

The update was furnished via a Form 6-K alongside a press release. The disclosure highlights the scale of the collaboration and the royalty-bearing structure on a multi-asset biosimilar portfolio, indicating a broad, long-term commercial framework with Sandoz.

Insights

Biopharma partnerships analyst

Large, multi-asset biosimilar pact with milestone and royalty potential.

Evotec announced a final agreement with Sandoz covering a portfolio of up to 10 biosimilar molecules. The company states the arrangement could yield payments potentially over US$ 650 m, plus royalties. This pairing combines Evotec’s development capabilities with Sandoz’s biosimilar focus.

Payments framed as “potentially over” and royalties typically depend on program progress and commercialization outcomes. Portfolio breadth (up to 10 molecules) spreads risk across multiple assets.

Key disclosed markers are the US$ 650 m potential and royalty component; actual financial results will hinge on advancement and market uptake of each biosimilar.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November, 2025

COMMISSION FILE NUMBER 001-34041

Evotec SE
(Translation of registrant’s name into English)

Essener Bogen 7

22419 Hamburg

Germany

Tel: +49 40 560810
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

On November 04, 2025, Evotec SE (the “Company”) issued a press release announcing final agreement with Sandoz attached hereto as Exhibit 99.1.

EXHIBIT INDEX

Exhibit	Description of Exhibit
99.1	In a landmark industry transaction, Evotec signs agreement with Sandoz, resulting in payments potentially over US$ 650 m plus royalties on portfolio of up to 10 biosimilar molecules

SIGNATURE

Pursuant to the requirements, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Evotec SE
	By:	/s/ Christian Wojczewski
		Name: Christian Wojczewski
		Title: Chief Executive Officer

Date: November 04, 2025

FAQ

What did Evotec (EVO) announce in its Form 6-K?

Evotec announced a final agreement with Sandoz, with payments potentially over US$ 650 m plus royalties on a portfolio of up to 10 biosimilar molecules.

How large is the potential payment value mentioned by Evotec (EVO)?

The company cites payments potentially over US$ 650 m, in addition to royalties.

How many biosimilar molecules are included in the Evotec-Sandoz agreement?

The portfolio covers up to 10 biosimilar molecules.

Does the Evotec (EVO) update mention royalties?

Yes. Evotec states the agreement includes royalties on the biosimilar portfolio.

What filing did Evotec (EVO) use to share this information?

Evotec furnished a Form 6-K with an attached press release (Exhibit 99.1).

Is the Evotec-Sandoz deal described as finalized?

Yes. Evotec describes it as a final agreement with Sandoz.